Drug interactions between dasatinib and Femara
Results for the following 2 drugs: |
|
|---|---|
| dasatinib | |
| Femara (letrozole) | |
Interactions between your selected drugs
letrozole ⇔ dasatinib
Applies to: Femara (letrozole) and dasatinib
MONITOR: Coadministration with dasatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dasatinib, which is a time-dependent inhibitor of the isoenzyme. In a pharmacokinetic study of 54 healthy subjects, administration of simvastatin with a single 100 mg dose of dasatinib increased the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of simvastatin by 37% and 20%, respectively, compared to administration without dasatinib. MANAGEMENT: Caution is advised if dasatinib must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dasatinib is added to or withdrawn from therapy.
See also...
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2009 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
